Pharmaceutical Report Library l Report Store l Pharma Intelligence

Minimally Invasive Heart Valve Repair and Replacement Devices

This comprehensive medical market and technology report provides an overview and in-depth market analysis of the transcatheter heart valve products used in the treatment of heart valve stenosis, regurgitation, and other valvular disorders.

October 13, 2019

Find out more

Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

July 25, 2014

Find out more

Darolutamide

Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to ARs, blocking nuclear translocation of ARs and AR-mediated gene expression. The AR signaling pathway is the primary pathway that drives prostate cancer growth.

January 18, 2018

Find out more

Contract Research Organizations: Health and Wealth in 2013

$5,000.00

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.

November 3, 2016

Find out more

Wound Care: Advanced Dressings and Closure Products

$4,750.00

In 2019, sales of advanced wound care products in the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Rest of World markets totaled nearly $8.2bn;

November 9, 2020

Find out more

adagloxad simolenin

Adagloxad simolenin (OBI Pharma) is a carbohydrate-based vaccine comprised of Globo-H conjugated to keyhole limpet hemocyanin. Upon exposure to the synthetic Globo-H vaccine and an immunological adjuvant, the immune system mounts IgM and IgG responses against Globo-H hexasaccharide.

February 26, 2020

Find out more

Anoro

GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).

July 31, 2018

Find out more

R&D Trends 2016

$2,995.00

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.

October 17, 2016

Find out more

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

$599.00

A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Find out more

Lonasen

Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist.

March 19, 2018

Find out more

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

$599.00

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

March 9, 2017

Find out more

Spinal Motion Preservation Devices Market

$4,750.00

Sales of spinal motion preservation devices totaled $1.7bn in 2019, with sales expected to climb at a CAGR of 2.0% during 2019-2024.

May 20, 2020

Find out more

Inhalation Drug Delivery Devices Market

$4,750.00

The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million. The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period. Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.

July 19, 2017

Find out more

fostemsavir

Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells.

June 28, 2019

Find out more

Keytruda

Keytruda is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.

February 26, 2020

Find out more

Report library

Minimally Invasive Heart Valve Repair and Replacement Devices

Dyslipidemia KOL Insight Interview #1

Darolutamide

Contract Research Organizations: Health and Wealth in 2013

Wound Care: Advanced Dressings and Closure Products

adagloxad simolenin

Anoro

R&D Trends 2016

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

Lonasen

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Spinal Motion Preservation Devices Market

Inhalation Drug Delivery Devices Market

fostemsavir

Keytruda